Elan plans new Tysabri study after FDA green light
Pharmaceutical companies Elan and Biogen plan to begin a new international study of multiple sclerosis drug Tysabri in the coming weeks after the US Food and Drug Administration (FDA) removed the hold on clinical trial dosing of the drug.
The two companies had previously voluntarily suspended Tysabri from the US market and all ongoing clinical trials based on reports of progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal disease of the central nervous system.
